Hi Ferret53.
First of all Oxycodone is now considered to be a superior drug for use by chronic pain sufferers than Morphine. Oxycodone is now the leading pain management drug and is currently administered in tablet or intravenous form and is more potent than morphine with fewer adverse effects.
From Wiki "Compared to morphine, oxycodone causes less respiratory depression, sedation, pruritus, nausea, and euphoria. As a result, it is generally better tolerated than morphine.....Oxycodone is one of several new semi-synthetic opioids ..and is an attempt to improve on the existing opiates and opioids: morphine, diacetylmorphine (heroin), and codeine."
The Oxycodone market which POH is targeting with its TPM Oxycodone patch is a USD $3.5 Billion market and is the drug of first choice by medical practioners for patients suffering prolonged and serious pain. Unfortunately it is also the drug of first choice by drug abusers which is a massive public health problem.
The POH TPM OXycodone patch has many many advantages over oral or intravenous delivery. The patch delivers less active with greater efficacy and can deliver sustained measured dosage for prolonged use. The patch is tamperproof and cannot be abused by those seeking to use it illegally for euphoric effect. The patch delivery bipasses the gut eliminating the side effects that typically occur with an oral delivery. The patch when removed allows rapid elimination of the Oxycodone from the blood stream. The patch is non irritating and causes no infection or skin disruption at site of application meaning improved patient compliance. The patch prevents overdosing because of the unique slow release of the active systemically from the patch matrix.
Hope this answers our question
regs KC
- Forums
- ASX - By Stock
- AVE
- tpm 02 insulin
tpm 02 insulin, page-23
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.001(25.0%) |
Mkt cap ! $9.507M |
Open | High | Low | Value | Volume |
0.3¢ | 0.3¢ | 0.3¢ | $2.035K | 678.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
28 | 40284733 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 39213269 | 30 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
28 | 40284733 | 0.002 |
31 | 73717741 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 39213269 | 30 |
0.004 | 30014232 | 16 |
0.005 | 10575266 | 9 |
0.006 | 10908952 | 10 |
0.007 | 13396103 | 7 |
Last trade - 13.19pm 13/11/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online